Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
Hoth Therapeutics (NASDAQ: HOTH) has partnered with Washington University School of Medicine in St. Louis on an NIH grant application to advance Alzheimer's disease research using HT-ALZ, an FDA-approved NK-1 receptor antagonist.
The research, led by Dr. Carla M. Yuede, aims to understand the mechanisms behind HT-ALZ's cognitive benefits. Preclinical studies have shown promising results:
- Significant improvement in cognitive functions
- Reduced anxiety-like behaviors
- Decreased astrocyte-driven neuroinflammation in APP/PS1 mouse models
- 15% reduction in brain interstitial fluid Aβ40 levels within 20 hours of acute treatment
The company has provided GMP-quality HT-ALZ to support the studies. If funded, the grant will investigate NK-1 receptor antagonism's cellular specificity and its potential for treating neuroinflammatory conditions.
Hoth Therapeutics (NASDAQ: HOTH) ha avviato una collaborazione con la Washington University School of Medicine di St. Louis per una domanda di finanziamento NIH per avanzare nella ricerca sulla malattia di Alzheimer utilizzando HT-ALZ, un antagonista del recettore NK-1 approvato dalla FDA.
La ricerca, guidata dalla Dr.ssa Carla M. Yuede, si propone di comprendere i meccanismi alla base dei benefici cognitivi di HT-ALZ. Gli studi preclinici hanno mostrato risultati promettenti:
- Significativo miglioramento delle funzioni cognitive
- Riduzione dei comportamenti simili all'ansia
- Decremento della neuroinfiammazione indotta dagli astrociti nei modelli murini APP/PS1
- Riduzione del 15% dei livelli di Aβ40 nel fluido interstiziale cerebrale entro 20 ore dal trattamento acuto
La società ha fornito HT-ALZ di qualità GMP per supportare gli studi. Se finanziato, il grant esplorerà la specificità cellulare dell'antagonismo del recettore NK-1 e il suo potenziale per il trattamento delle condizioni neuroinfiammatorie.
Hoth Therapeutics (NASDAQ: HOTH) se ha asociado con la Washington University School of Medicine en St. Louis para una solicitud de subvención del NIH para avanzar en la investigación sobre la enfermedad de Alzheimer utilizando HT-ALZ, un antagonista del receptor NK-1 aprobado por la FDA.
La investigación, liderada por la Dra. Carla M. Yuede, tiene como objetivo entender los mecanismos detrás de los beneficios cognitivos de HT-ALZ. Los estudios preclínicos han mostrado resultados prometedores:
- Mejoras significativas en las funciones cognitivas
- Reducción de comportamientos similares a la ansiedad
- Disminución de la neuroinflamación inducida por astrocitos en modelos de ratón APP/PS1
- Reducción del 15% en los niveles de Aβ40 en el líquido intersticial cerebral en 20 horas tras el tratamiento agudo
La empresa ha proporcionado HT-ALZ de calidad GMP para apoyar los estudios. Si se financia, la subvención investigará la especificidad celular del antagonismo del receptor NK-1 y su potencial para tratar condiciones neuroinflamatorias.
Hoth Therapeutics (NASDAQ: HOTH)는 워싱턴 대학교 의과대학과 협력하여 NIH 보조금 신청을 통해 HT-ALZ를 사용한 알츠하이머병 연구를 발전시키고 있습니다. HT-ALZ는 FDA에서 승인된 NK-1 수용체 길항제입니다.
이 연구는 Carla M. Yuede 박사가 이끌며, HT-ALZ의 인지적 이점 뒤에 있는 메커니즘을 이해하는 것을 목표로 하고 있습니다. 전임상 연구는 유망한 결과를 보여주었습니다:
- 인지 기능의 유의미한 개선
- 불안 유사 행동의 감소
- APP/PS1 생쥐 모델에서 아스트로사이트 유도 신경 염증의 감소
- 급성 치료 후 20시간 이내에 뇌 간질액 Aβ40 수치 15% 감소
회사는 연구를 지원하기 위해 GMP 품질의 HT-ALZ를 제공했습니다. 자금 지원이 이루어지면, 이 보조금은 NK-1 수용체 길항제의 세포 특이성과 신경 염증 상태 치료 가능성을 조사할 것입니다.
Hoth Therapeutics (NASDAQ: HOTH) s'est associé à la Washington University School of Medicine à St. Louis pour une demande de subvention NIH visant à faire progresser la recherche sur la maladie d'Alzheimer en utilisant HT-ALZ, un antagoniste du récepteur NK-1 approuvé par la FDA.
La recherche, dirigée par la Dr. Carla M. Yuede, vise à comprendre les mécanismes sous-jacents aux bénéfices cognitifs de HT-ALZ. Les études précliniques ont montré des résultats prometteurs :
- Amélioration significative des fonctions cognitives
- Réduction des comportements similaires à l'anxiété
- Diminution de la neuroinflammation induite par les astrocytes dans les modèles murins APP/PS1
- Réduction de 15 % des niveaux d'Aβ40 dans le liquide interstitiel cérébral dans les 20 heures suivant le traitement aigu
L'entreprise a fourni HT-ALZ de qualité GMP pour soutenir les études. Si le financement est accordé, la subvention examinera la spécificité cellulaire de l'antagonisme du récepteur NK-1 et son potentiel pour traiter les conditions neuroinflammatoires.
Hoth Therapeutics (NASDAQ: HOTH) hat sich mit der Washington University School of Medicine in St. Louis zusammengetan, um einen NIH-Zuschussantrag zur Förderung der Alzheimer-Forschung mit HT-ALZ, einem von der FDA zugelassenen NK-1-Rezeptorantagonisten, zu stellen.
Die Forschung, geleitet von Dr. Carla M. Yuede, zielt darauf ab, die Mechanismen hinter den kognitiven Vorteilen von HT-ALZ zu verstehen. Präklinische Studien haben vielversprechende Ergebnisse gezeigt:
- Signifikante Verbesserung der kognitiven Funktionen
- Verringerung von angstähnlichem Verhalten
- Verminderte von Astrozyten verursachte Neuroinflammation in APP/PS1-Mausmodellen
- 15%ige Reduzierung der Aβ40-Spiegel im Gehirninterstitium innerhalb von 20 Stunden nach akuter Behandlung
Das Unternehmen hat HT-ALZ in GMP-Qualität bereitgestellt, um die Studien zu unterstützen. Wenn der Zuschuss genehmigt wird, wird untersucht, wie spezifisch die Zellwirkung des NK-1-Rezeptorantagonismus ist und welches Potenzial er für die Behandlung neuroinflammatorischer Erkrankungen hat.
- FDA-approved NK-1 receptor antagonist shows promising preclinical results
- 15% reduction in brain interstitial fluid Aβ40 levels in acute treatment
- Significant cognitive improvement and reduced neuroinflammation in mouse models
- Potential NIH grant funding could accelerate research and development
- Still in early preclinical stage, far from market approval
- NIH grant funding not yet secured
- Efficacy in human patients remains unproven
Insights
Hoth Therapeutics' collaboration with Washington University represents an interesting strategic approach to Alzheimer's disease through drug repurposing. The company is leveraging HT-ALZ, an FDA-approved NK-1 receptor antagonist, which potentially offers a faster development pathway compared to novel compounds.
The preclinical data shows promise on multiple fronts: improved cognitive functions, reduced anxiety-like behaviors, and decreased neuroinflammation in mouse models. Particularly noteworthy is the
The NIH grant application, if successful, would provide valuable non-dilutive funding to further investigate the cellular mechanisms behind HT-ALZ's effects. This approach to targeting neuroinflammation through NK-1 receptor antagonism represents a differentiated strategy in the Alzheimer's treatment landscape, which has historically seen many failures with amyloid-focused approaches.
The use of GMP-quality material in preclinical studies demonstrates methodological rigor and suggests the company is positioning for potential future regulatory submissions. However, investors should understand that despite promising preclinical findings, the path from mouse models to successful human Alzheimer's treatments remains challenging and lengthy.
For Hoth Therapeutics, a micro-cap company with approximately
The repurposing strategy for HT-ALZ is financially prudent, leveraging an already FDA-approved compound with established safety profiles to potentially reduce development costs, risks, and timelines. This approach is particularly important for small biopharma companies with capital resources.
The Washington University collaboration enhances scientific credibility, which could positively influence future capital raising efforts or partnership discussions. However, this announcement represents early-stage research advancement rather than near-term revenue potential.
While Alzheimer's disease represents a substantial market opportunity with significant unmet needs, investors should recognize that this program remains in preclinical development with years of potential development ahead before commercialization. This announcement, while positive, indicates continual progress rather than a transformative catalyst for Hoth's valuation.
The research collaboration is led by Dr. Carla M. Yuede, Professor in the Departments of Psychiatry, Neurology, and Neuroscience, and Director of the Animal Behavior Core at
In preclinical studies conducted at
Robb Knie, Chief Executive Officer of Hoth Therapeutics, commented, "We are proud to support Dr. Yuede and her team at
The company has supplied GMP-quality HT-ALZ to
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-collaborates-with-washington-university-on-nih-grant-application-advancing-alzheimers-program-using-nk-1-receptor-antagonist-ht-alz-302417942.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What are the key findings from HT-ALZ preclinical trials for Alzheimer's treatment?
How does Hoth Therapeutics' HT-ALZ work in treating Alzheimer's disease?
What is the focus of HOTH's collaboration with Washington University?
What stage of development is HOTH's Alzheimer's treatment HT-ALZ in?
